Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Sacituzumab Govitecan + Capecitabine for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This trial is testing a new combination of drugs, sacituzumab govitecan and capecitabine, for patients with advanced gastrointestinal cancers that have not responded to standard treatments. Researchers
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service